Physician Views: Assessing the outlook for Novartis' Entresto
Novartis has gained earlier than expected US approval for its new heart failure treatment Entresto, which is forecast to be the biggest new drug approval of 2015.
Much initial focus is on the pricing of Entresto, which at a cost of around $12 a day is significantly more expensive that current standard of care therapies. A month's supply of generic enalapril – the comparator drug in Novartis' approval-supporting PARADIGM-HF study – is available at a cost of around $4.
The Swiss company has earned the opportunity to price Entresto at a significant premium, argues Pfizer's former head of R&D John LaMattina, given the mortality benefits it has demonstrated versus the most widely used current therapy option. Furthermore, Novartis has discussed the introduction of risk-sharing price agreements with select payers, which could see the price of the drug increase if Entresto reduces hospitalisation rates (Spotlight On: Can Novartis' Entresto revive risk-share pricing deals in the post-Sovaldi US market).
This provides a tangible benchmark of the potential efficacy benefits that Entresto offers for the treatment of heart failure. Efficacy of the drug – and how it is viewed and utilised by physicians – will nevertheless come under scrutiny in light of its price.
Reasons to Purchase
Following FDA approval of Entresto (and in anticipation of EU approval), we are asking both US and EU5-based cardiologists and primary care practitioners the following questions…
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook